Shaping the future of medical intervention.
Over the past 50 years, the introduction of new technologies has ushered in the era of minimally invasive techniques and procedures. Despite accessing the body in less invasive ways, all too often physicians are required to sacrifice healthy tissue, perform multiple interventions, and endure numerous tradeoffs while diagnosing and treating disease.
With the Monarch Platform, Auris will empower physicians with precision and consistency of care across medical intervention. The Monarch Platform improves upon existing minimally invasive techniques by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform to enable new categories of care. Every element of our technology is driven by patient-centric design aimed at maintaining the integrity of the human body.
Auris Health was acquired by Ethicon, part of the Johnson & Johnson Medical Devices Companies, in 2019. Auris was founded by Dr. Frederic Moll, a physician and visionary entrepreneur with an unrelenting passion and drive for improving patient outcomes. Dr. Moll pioneered the field of surgical robotics starting his first robotics company in 1995. Under Dr. Moll’s leadership, Auris is committed to tackling some of the biggest problems in healthcare. We are developing solutions for a multitude of disease states where the standard treatments may be inconsistent and sub-optimal.
Lung cancer is the first disease in our sight. More patients die every year from lung cancer than from prostate, breast and colon cancer combined. Lung cancer is so deadly because it is usually diagnosed late and treatment can be ineffective. Auris designed the Monarch Platform to allow physicians to accurately access small and hard-to-reach lung nodules early, for diagnosing and targeting treatment.
At Auris, the future of medical intervention has arrived.
Ethicon, part of Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 100 years from creating the first sutures, to revolutionizing surgery with minimally invasive procedures. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world's most pressing health care issues and improve and save more lives. Through Ethicon's surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity worldwide, we deliver innovation to make a life-changing impact. For more information, visit www.ethicon.com.
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
Frederic H. Moll, M.D. is the Chief Development Officer for Johnson & Johnson Medical Devices Companies. Fred Moll co-founded Auris and before it was acquired by Johnson & Johnson, he was the CEO of Auris. Prior to Auris, Dr. Moll was a founder of three public companies; Hansen Medical (HNSN) Restoration Robotics (HAIR) and Intuitive Surgical (ISRG). Prior to Intuitive, he served as a founder and medical director of Origin Medsystems, acquired by Eli Lily, and Endotherapeutics, acquired by United States Surgical.
We are creating a new future.
Bronchoscopy Important Safety Statement:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology Important Safety Statement:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.